HK Stock Market Move | XUNCE (03317) rose over 5% during trading, and Deutsche Bank maintains a "Buy" rating with a target price of HKD 351.
On August 26, Xunce (03317) rose over 5%, reaching a peak of 127 Hong Kong dollars.
On August 26, XUNCE (03317) rose over 5%, reaching a high of 127 Hong Kong dollars. As of the time of writing, it is up 5%, priced at 126 Hong Kong dollars, with a trading volume of 97.4539 million Hong Kong dollars.
In terms of news, Deutsche Bank recently released a research report, maintaining a "Buy" rating for XUNCE and setting a target price of 351 Hong Kong dollars, expressing optimism about its Token business model and vertical industry layout.
The report indicated that the company's performance in the first half of 2026 met expectations, driven by the implementation of enterprise AI infrastructure, cross-industry replication, and the Token business model, with revenue increasing by 389% year-on-year to 967 million yuan. Adjusted net profit is 67 million yuan, marking the first half-year profit. Customer ARPU increased by 240% year-on-year to 5.56 million yuan, customer retention rate remained above 90%, and revenue per capita rose by 379% year-on-year, significantly enhancing the company's operational efficiency.
Related Articles

HK Stock Market Move | ITC PROPERTIES (00199) rose over 9% in early trading. The company is holding an investor open day today, focusing on new developments in the NEOCLOUD transformation.

Waterdrop, Inc. ADR Class A (WDH.US) aims to address the clinical recruitment challenges in extensive-stage small cell lung cancer through Yi Fan Pharmaceutical, setting a new standard for services.

SHIYUE DAOTIAN (09676) reported revenue of 3.814 billion yuan in the first half of the year, leading to a model-driven valuation reassessment.
HK Stock Market Move | ITC PROPERTIES (00199) rose over 9% in early trading. The company is holding an investor open day today, focusing on new developments in the NEOCLOUD transformation.

Waterdrop, Inc. ADR Class A (WDH.US) aims to address the clinical recruitment challenges in extensive-stage small cell lung cancer through Yi Fan Pharmaceutical, setting a new standard for services.

SHIYUE DAOTIAN (09676) reported revenue of 3.814 billion yuan in the first half of the year, leading to a model-driven valuation reassessment.

RECOMMEND





